Cholesterol Targeted Catalytic Hydrogel Fueled by Tumor Debris can Enhance Microwave Ablation Therapy and Anti‐Tumor Immune Response
Advanced Science · 2025
DOI: 10.1002/advs.202406975 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Lin Shen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Key Laboratory of Imaging and Interventional Medicine, Zhejiang Engineering Research Center of Interventional Medicine Engineering and Biote…. Hauptthemen laut MEDLINE: Cholesterol, Hydrogels, Microwaves, Liver Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: "Pioneer" and "Leading Goose" R&D Program of Zhejiang, Medical Science and Technology Project of Zhejiang Province, Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
The immunosuppressive residual tumor microenvironment (IRTM) is a key factor in the high recurrence and metastasis rates of hepatocellular carcinoma (HCC) after microwave ablation (MWA). Cholesterol‐rich tumor fragments significantly contribute to IRTM deterioration. This study developed a cholesterol‐targeted catalytic hydrogel, DA‐COD‐OD‐HCS, to enhance the synergy between MWA and immune checkpoint inhibitors (ICIs) for HCC treatment. Cholesterol oxidase (COD), modified with dimethyl maleic anhydride (DA) for release in acidic IRTM, is used to degrade cholesterol. Oxydextran (OD) and hemin‐chitosan (HCS) formed a dual network gel, ensuring long‐term fixation of COD and hemin in the IRTM post‐MWA. In both in vitro and in vivo HCC models, DA‐COD‐OD‐HCS effectively released COD, degraded cholesterol, and induced tumor cell ferroptosis, enhancing the antitumor immune response. Combined with anti‐PD‐L1 immunotherapy, this strategy inhibited primary tumor growth and distant metastases, without side effects on adjacent tissues. This work highlights that cholesterol‐targeting catalytic hydrogels fueled by tumor debris can significantly improve the efficacy of MWA and ICIs, offering a novel therapeutic approach for HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Zhejiang Key Laboratory of Imaging and Interventional Medicine, Zhejiang Engineering Research Center of Interventional Medicine Engineering and Biotechnology, The Fifth Affiliated Hospital of Wenzhou Medical University,…
- Clinical College of The Affiliated Central Hospital, School of Medicine, Lishui University, Lishui, 323000, P. R. China.
- Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Soochow University, Suzhou, Jiangsu, 215123, P. R. China.
ORCID-Profile: Lin Shen, Jiansong Ji
Förderung
- "Pioneer" and "Leading Goose" R&D Program of Zhejiang
- Medical Science and Technology Project of Zhejiang Province
- Natural Science Foundation of Zhejiang Province
- Postdoctoral Science Foundation of Jiangsu Province
- National Natural Science Foundation of China
Zitieren
APA
Shen, L., Yang, Z., Zhong, Y., Bi, Y., Yu, J., Lu, Q., Su, Y., Chen, X., Zhao, Z., Shu, G., Chen, M., Cheng, L., Feng, L., Lu, C., Liu, Z., & Ji, J. (2025). Cholesterol Targeted Catalytic Hydrogel Fueled by Tumor Debris can Enhance Microwave Ablation Therapy and Anti‐Tumor Immune Response. Advanced Science. https://doi.org/10.1002/advs.202406975
Vancouver
Shen L, Yang Z, Zhong Y, Bi Y, Yu J, Lu Q, et al. Cholesterol Targeted Catalytic Hydrogel Fueled by Tumor Debris can Enhance Microwave Ablation Therapy and Anti‐Tumor Immune Response. Advanced Science. 2025. doi:10.1002/advs.202406975
BibTeX
@article{Shen2025,
author = {Shen, Lin and Yang, Zhijuan and Zhong, Yi and Bi, Yanran and Yu, Junchao and Lu, Qinwei and Su, Yanping and Chen, Xiaoxiao and Zhao, Zhongwei and Shu, Gaofeng and Chen, Minjiang and Cheng, Liang and Feng, Liangzhu and Lu, Chenying and Liu, Zhuang and Ji, Jiansong},
title = {Cholesterol Targeted Catalytic Hydrogel Fueled by Tumor Debris can Enhance Microwave Ablation Therapy and Anti‐Tumor Immune Response},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202406975}
}
EUVIMED